Trials / Active Not Recruiting
Active Not RecruitingNCT05916365
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Almirall, S.A. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of the study is to assess the long-term tolerability and effectiveness of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD). Participants who complete the last assessment visit in ADjoin (Week 100) will be offered the opportunity to enroll in this extension study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Lebrikizumab | Lebrikizumab solution for injection administered subcutaneously |
Timeline
- Start date
- 2023-05-23
- Primary completion
- 2026-03-01
- Completion
- 2026-04-01
- First posted
- 2023-06-23
- Last updated
- 2025-05-02
Locations
32 sites across 2 countries: Germany, Poland
Source: ClinicalTrials.gov record NCT05916365. Inclusion in this directory is not an endorsement.